I would give $Novavax(NVAX)$a miss, as I prefer established pharmaceutical companie with a line of cash cows from approved drugs proven to treat common diseases and a long pipeline of drugs in various stages of clinical trials.
Examples of my preference are $Pfizer(PFE)$and $Merck(MRK)$that do not rely on a single drug for profitability, and whose earnings are stable. This is unlike Novavax which depends on the success of its COVID-19 vaccine and whose share price is highly volatile due to the high dependency on a single drug. This is not helped by the lateness of its COVID-19 vaccine, that falls far behind those of Pfizer, $BioNTech SE(BNTX)$and $Moderna, Inc.(MRNA)$that have been widely adopted by the western countries.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Ok
👌
Ok
Good